arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

GENELUX Corp

GNLX
$2.66 ▼ -0.03 (-1.12%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
5 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

GENELUX Corp faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $98.9M
Dividend Yield
Revenue Growth 0.0%
Op. Margin None
ROIC -227.3%
FCF / Share $-0.71
Trailing P/E
Price / Book 8.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.00K
— 0.0%
Net Income Profit after all expenses
$-32.15M
↓ -7.6%
FCF / Share Free cash flow per share
$-0.71
↓ -3.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters